NCT00723528 – A Placebo-Controlled Double-Blind Comparative Study of CNTO1275 in Patients With Plaque Type Psoriasis Posted on July 3, 2018 by tsuperadmin -
NCT01550744 – A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a “Subject-tailored” Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis Posted on July 3, 2018 by tsuperadmin -
NCT01483599 – A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE) Posted on February 27, 2018 by tsuperadmin -
NCT00307437 – A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis Posted on May 9, 2017 by tsuperadmin -
NCT00267969 – A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis Posted on May 8, 2017 by tsuperadmin -
NCT01077362 – A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents Posted on July 28, 2015 by tsuperadmin -
NCT01009086 – A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis Posted on July 28, 2015 by tsuperadmin -
The YODA Project